Uptravi

Active Ingredient(s): Selexipag
FDA Approved: * December 21, 2015
Pharm Company: * ACTELION PHARMS LTD
Category: Blood Pressure

Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).[1] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[2] It is taken by mouth or administered intravenously.[1][3] Contents 1 Contraindications 2 Adv... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Uptravi 200 ug/1 Oral Tablet, Coated
NDC: 66215-602
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 400 ug/1 Oral Tablet, Coated
NDC: 66215-604
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 600 ug/1 Oral Tablet, Coated
NDC: 66215-606
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 800 ug/1 Oral Tablet, Coated
NDC: 66215-608
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 1000 ug/1 Oral Tablet, Coated
NDC: 66215-610
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 1200 ug/1 Oral Tablet, Coated
NDC: 66215-612
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 1400 ug/1 Oral Tablet, Coated
NDC: 66215-614
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 1600 ug/1 Oral Tablet, Coated
NDC: 66215-616
Labeler:
Actelion Pharmaceuticals Us, Inc.
Uptravi 1800 ug/10ml Intravenous Injection, Powder, for Solution
NDC: 66215-718
Labeler:
Actelion Pharmaceuticals Us, Inc.